6,027 research outputs found
Review of Structural Analysis and Design to Prevent Disproportionate Collapse by Feng Fu
Full text linkAdam Martínez, JM. (2016). Review of Structural Analysis and Design to Prevent Disproportionate Collapse by Feng Fu. Journal of Performance of Constructed Facilities. 07516003:1-2. doi:10.1061/(ASCE)CF.1943-5509.0000976S120751600
Unexpected pregnancy and ovarian hyperstimulation syndrome following IVF cycle with all embryos frozen : a case report
No full textComparative frequency of Coagulation Factor II and Coagulation Factor V Alleles among new-born and senior citizens
Full text linkResistance to activated protein C is one of the most common inherited disorders associated with hereditary thrombophilia. A missense mutation in the gene coding for coagulation factor V (CF V Leiden) and which renders this procoagulant factor resistant to inactivation by activated protein C results in an inherited risk for venous thrombosis. Recently, another mutation has been identified in the prothrombin gene (CF II G20210A) which was also associated with increased risk for venous thrombosis. In this study, we sought to establish the frequency of the two alleles in a random sample of Maltese newborn and compare these with the frequencies of the same alleles among senior citizens and patients with clinical thrombophilia. The control population of 554 newborn samples processed for the same point mutations gave 13 (2.3%) who were CF V Leiden heterozygotes and 7 (2.7%) who were CF II G20210A heterozygotes. Neither homozygotes nor trans-heterozygotes (i.e. CF V Leden and CF II2 0210A heterozygotes) were observed. The 348 senior citizens gave 9 (2.6%) CF V Leiden heterozygotes and 8 (2.4%) CF II G20210A heterozygotes. Neither homozygotes nor trans-heterozygotes (i.e. CF V Leden and CF II20210A heterozygotes) were observed. The 328 patients referred to the Laboratory of Molecular Genetics, University of Malta, with clinical thrombosis gave 23 (7.01%) CF V Leiden heterozygotes and 24 (7.31%) CF II G20210A heterozygous. One patient was found to be trans-heterozygous for the two mutations. The data suggested that although CF V G1691A and CF II G20210A may increase risk for thrombophilia, they do not impact on the survival of the carriers, but the transheterozygozity may also confer increased risk. The high allele frequency may be best explained by positive natural selection.peer-reviewe
Supplemental material for Standard Reference Line Combined with One-Point Calibration-Free Laser-Induced Breakdown Spectroscopy (CF-LIBS) to Quantitatively Analyze Stainless and Heat Resistant Steel
No full textSupplemental material for Standard Reference Line Combined with One-Point Calibration-Free Laser-Induced Breakdown Spectroscopy (CF-LIBS) to Quantitatively Analyze Stainless and Heat Resistant Steel by Hongbo Fu, Huadong Wang, Junwei Jia, Zhibo Ni and Fengzhong Dong in Applied Spectroscopy</p
Fo shuo fu mu en zhong jing 佛 說 父母 恩 重 經.
No full textFo shuo fu mu en zhong jing 佛 說 父 母 恩 重 經Fu mu en zhongjing 父 母 恩 重 經, cf. Fo shuo fu mu en zhong jingComplet en 1 j.T . 2887, vol. 85, pp. 1403b-1404 a. Sūtra apocryphe. A gauche du titre final, note en petits car. :« Copie due au bhikṣu Zhi zhao 智 照, le 29e jour du 11e mois de l'anding mao... » Écr. ordinaire, car. en hauteur. Encre très foncée. 60 col. en tout, 16 ou 17 car. par col. Marges sup.3,2 à 4 cm, inf. 3,1 à 4,2 cm. Réglure
Fo shuo fu mu en zhong jing 佛 說 父母 恩 重 經.
No full textFo shuo fu mu en zhong jing 佛 說 父 母 恩 重 經Fu mu en zhongjing 父 母 恩 重 經, cf. Fo shuo fu mu en zhong jingComplet en 1 j.T . 2887, vol. 85, pp. 1403b-1404 a. Sūtra apocryphe. A gauche du titre final, note en petits car. :« Copie due au bhikṣu Zhi zhao 智 照, le 29e jour du 11e mois de l'anding mao... » Écr. ordinaire, car. en hauteur. Encre très foncée. 60 col. en tout, 16 ou 17 car. par col. Marges sup.3,2 à 4 cm, inf. 3,1 à 4,2 cm. Réglure
[Qin fu yin / 秦 婦 吟 par Wei Zhuang 韋 莊].
No full textQin fu yin 秦 婦 吟. Wei Zhuang 韋 莊. PoésieNumérisation effectuée à partir d'un document original.Fragment. Déb. et fin manquent. Pour des copies plus complètes, cf. les Pelliot chinois 2700 et Pelliot chinois 3381. Cf. KTSL , pp.. 303-308 et LC , p. 644. Écr. kai maladroite. Encre foncée. 1 signe d'annulation. 1 signe d'inversion. Quelques ratures. 21 col., 20 à 24 car. par col. Marges sup. et inf. 0,1 cm
The influence of fiber-matrix adhesion on the linear viscoelastic creep behavior of CF/PPS composites
No full textThe influence of fiber-matrix adhesion on the linear viscoelastic creep behavior of as received and surface modified carbon fiber (AR-CF and SM-CF, respectively) reinforced polyphenylene sulfide (PPS) composite materials was investigated. Short-term tensile creep tests were performed on ±45° specimens under four different isothermal condition; 70, 80, 90 and 100°C. As a preliminary step to obtain the time-temperature master curve, as well as to characterize the changes in matrix dominated properties over storage time, physical aging effects were evaluated on both systems using the short-term test method established by Struik. The results showed that the surface treatment carried out in the SM-CF improved fiber-matrix adhesion, enhancing the mechanical performance of CF/PPS composites but with minor effects on the creep response. Increasing retardation times with physical aging was observed in all test conditions. Compared to temperature effects, physical aging showed to have a small contribution on the creep behavior of CF/PPS composites.Aerospace Structures & MaterialsAerospace Engineerin
Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre.
No full text 126 Background: The optimal CRT regimen for neoadjuvant or definitive treatment of locoregional esophageal or gastroesophageal junctional (GEJ) cancer is uncertain. There has been no direct comparison between concurrent Cisplatin/5-FU (CF) as per the CALGB 9781 trial (50.4 Gy) or Carboplatin/Paclitaxel (CP) as per the CROSS trial (41.4 Gy). Methods: A retrospective analysis comparing CF and CP was performed in all patients (pts) with locoregional esophageal or GEJ cancer treated in 2012-2014. Overall survival (OS) and disease-free survival (DFS) were assessed via uni- and multivariable Cox proportional hazards regression, adjusting for age, performance status and Charlson comorbidity index. Pathological complete response (pCR) rates were compared using Fisher’s exact test. Results: 64/86 (74%) pts were male. Median age was 64 years (range: 34-84). Primary sites were esophageal (56%, with 60% squamous histology) and GEJ (44%, with 11% squamous). 22 pts received CRT in 2012 (100% CF), 33 pts in 2013 (58% CF, 42% CP) and 31 pts in 2014 (16% CF, 84% CP). Surgery was undertaken in 19 (41%) CF and 27 (68%) CP pts. Median follow-up was 38 months. We found no significant OS difference between CF and CP overall (HR 0.82, 95% CI: 0.43-1.56, p = 0.55) or in the subgroup having surgery (n = 46; HR 2.01, 95% CI: 0.62-6.55, p = 0.25). However, in the subgroup without surgery (n = 40), CF (n = 27) was superior to CP (n = 13)(HR 0.11, 95% CI: 0.03-0.38, p < 0.001). OS was similar by histology (adenocarcinoma/squamous) in all-comers (p = 0.96), and in CF (p = 0.66) and CP subgroups (p = 0.66). DFS results were similar to OS. There was a non-significant numerical difference in pCR rates between CF (31%) and CP (18%) (p = 0.45). Conclusions: Survival is similar for CF and CP CRT regimens in patients undergoing trimodality therapy. pCR rates were comparable but lower than previously reported. In contrast, in the absence of surgical resection, CP given for CRT results in significantly inferior outcomes. Clinicians may prefer CP for surgical candidates given its toxicity profile. However, when treating with definitive CRT, CF may be preferable to CP as a standard regimen. </jats:p
- …
